Trejo-Arteaga A, Castorena-Arellano GA, Gutiérrez-Acar H, Muñoz-Pérez H

Language: Spanish
References: 12
Page: 143-146
PDF size: 916.86 Kb.

ABSTRACT

Introduction: Postoperative Residual Neuromuscular Block (PRNB) is a complication following the use of neuromuscular blocking agents. Objective: to compare the reversal time of rocuronium-induced neuromuscular block with sugammadex versus neostigmine in laparoscopic surgery anesthesia in obese patients. Material and methods: 21 patients with a body mass index ≥ 30 kg/m² were included, divided into two groups: group SUG (n = 11) treated with sugammadex at 2 mg/kg based on corrected body weight, and group NEO (n = 10) with neostigmine at 40 µg/kg. Neuromuscular function was monitored in the Post-Anesthesia Care Unit (PACU) at 0, 15, 30, and 60 minutes. Results: the mean time to achieve Train of Four (TOF) ≥ 0.9 was 2 minutes 5.4 seconds in group SUG and 8 minutes 5.5 seconds in group NEO (p < 0.05). The frequency of PRNB in the PACU for group NEO was 50, 80, 90, and 80%, while it did not occur in group SUG (p < 0.05). Conclusions: the reversal of rocuronium-induced neuromuscular block in obese patients undergoing laparoscopic surgery was significantly faster with sugammadex. Unlike neostigmine, in cases of moderate neuromuscular blockade, sugammadex effectively prevents PRNB.

REFERENCES

1. Pasic E, Castorena-Arellano G, Calderón-Vidal M. Incidencia y factores de riesgo para la parálisis residual post-operatoria. Rev Mex Anest. 2011;34:270-273.

2. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120-128.

3. Barajas R, Camarena J, Castellanos A, Castilleros OA, Castorena G, De Anda D, et al. Determinación de la incidencia de la parálisis residual postanestésica con el uso de agentes bloqueadores neuromusculares en México. Rev Mex Anest. 2011;34:181-188.

4. Claudius C, Garvey LH, Viby-Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia. 2009;64:10-21. doi: 10.1111/j.1365-2044.2008.05866.x.

5. Ali HH, Utting JE, Gray TC. Stimulus frequency in the detection of neuromuscular block in humans. Br J Anaesth. 1970;42:967-77.

6. Fuchs-Buder T, Schreiber JU, Meistelman C. Monitoring neuromuscular block: an update. Anaesthesia. 2009;64:82-89.

7. Kopman F, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia, 2009;64:22-30.

8. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109:816-824.

9. Booij LH. Cyclodextrins and the emergence of sugammadex. Anaesthesia. 2009;64:31-37.

10. Gaszynski T, Szewczyk T, Gaszynski W. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. Br J Anaesth. 2012;108:236-239.

11. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008;100:622-530. doi: 10.1093/bja/aen037.

12. Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth. 2006;97:160-163.